Aclaris Therapeutics vs Spyre Therapeutics
ACRS and SYRE side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACRS and SYRE compare
Spyre Therapeutics is the larger company, worth 15 times as much as Aclaris Therapeutics ($8.5B against $584M).
Spyre Therapeutics scores higher on the StockData Score (7 against 5 for Aclaris Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACRS | SYRE |
|---|---|---|
| Size and price | ||
| Market cap | $584M | $8.5B |
| Share price | $3.97 | $96.56 |
| Change, 1 year | 69.7% | 305% |
| Change, 5 years | −75.9% | −47.2% |
| Beta (5Y) | 1.15 | 1.47 |
| Employees | 73 | 102 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 71.1× | – |
| P/B | 4.7× (better) | 7.7× |
| FCF yield | −10.6% | – |
| Fair value | $1.45 | – |
| Margin of safety | −173% | – |
| Growth | ||
| Revenue growth (TTM) | −51.0% | – |
| Revenue growth, 5Y average | 3.8% | – |
| Profitability | ||
| Gross margin | 79.5% | – |
| Operating margin | −1050% | – |
| Net margin | −921% | – |
| FCF margin | −757% | – |
| Return on equity | −59.1% | −23.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 3.46 | 18.53 (better) |
| Altman Z-score | −2.58 | 70.18 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 82.3% | 109% |
| Held by insiders | 13.3% | 20.4% |
| Insider net buying, 12 months | −$1.4M (better) | −$437M |
| Short interest, % of float | 14.2% | 18.3% |
Go deeper
- ACRS stock overview
- ACRS income statement
- ACRS valuation and score
- SYRE stock overview
- SYRE income statement
- SYRE valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.